The lineage of a somatic cell can be altered by targeting its signaling networks with small molecules and/or genetically altering the expression of key transcription factors. Depending on the combination of factors, fibroblasts can be fully reprogrammed into induced pluripotent stem (iPS) cells or directly converted into specific cell lineages, bypassing the pluripotent state. The generation of defined target cells will enormously benefit patients who require cell transplantation therapy. In the decade, since iPS cells were first generated, many cell types have been induced from fibroblasts by direct conversion, including hepatocytes. Converted hepatocytelike cells have been shown to repopulate liver tissues after transplantation in mouse liver disease models, suggesting promise for future application in humans. Thus, to realize safe and efficient cell transplantation therapy, various methods for generating hepatocyte-like cells are being developed. In this review, we summarize the current methods for the generation of hepatocyte-like cells via cell fate modification using extrinsic factors.
It has long been thought that cell fate is irreversibly determined. However, advances over the past half century, such as nuclear transfer (1), cell fusion (2) and factor-mediated reprogramming (3) , have revealed the plasticity of cell identity (4) . Factor-mediated reprogramming was first demonstrated in vitro by converting fibroblasts to myoblasts via forced expression of the transcription factor (TF) MyoD (3), which is critical for specification of the skeletal muscle lineage during early development (5). Takahashi et al. achieved full reprogramming in fibroblasts and generated induced pluripotent stem (iPS) cells via ectopic expression of 'Yamanaka' transcription factors Oct4 (Pou5f1), Sox2, Klf4 and c-Myc (6) . The selected genes are core TFs that maintain self-renewal in embryonic stem (ES) cells (6) . Based on these studies, researchers hypothesized that forced expression of lineage-specific TFs could convert fibroblasts into other target somatic lineages. Indeed, additional sets of TFs have been identified that induce specific somatic cell phenotypes from fibroblasts, such as cardiomyocytes (7), cardiac progenitor cells (8) , haematopoietic progenitors (9, 10) , glutamatergic neurons (1114), dopaminergic neurons (15, 16) , motor neurons (17) , neural progenitors (18, 19) , angioblast-like progenitor cells (20) and osteoblasts (21) , in addition to hepatocytes (2225) and bipotent hepatic progenitors (26) . Hepatocytes and cortical astrocytes also retain plasticity, which allows them to be converted to neurons (27) , and glutamatergic (28) and GABAergic (28, 29) neurons, respectively.
Following development of TF-mediated conversion, an alternative method of cell fate conversion was established utilizing small molecules to avoid integration of viral carrier DNA in the genome. Transgene integration in reprogrammed cells could lead to tumorigenesis, immune rejection, or unintended phenotypes caused by aberrant gene expression. Cell signaling alteration with small molecules is expected to reduce these risks. In fact, fibroblasts were converted to pancreatic b cells (30), neurons (3133), neural stem/progenitor cells (34, 35) , endothelial cells (36) and cardiomyocytes (37, 38) using only small molecules. In addition to these cell fate conversions between somatic cells, small molecules are capable of reprogramming fibroblasts to pluripotency (39, 40) . These studies suggest that any cell type can be generated from fibroblasts through specific alteration of signaling networks by small molecules. This strategy holds enormous benefits for regenerative medicine. Methods for lineage conversion have progressed in the field of liver regeneration in particular, with evidence of in vivo direct conversion (41, 42) and in vitro generation of chemically induced liver progenitor (CLiP) cells from differentiated hepatocytes (43) . This review summarizes current progress on generating cell sources for curing liver diseases via TF-and small molecule-mediated fate conversion.
Conversion of Fibroblasts to HepatocyteLike Cells by TFs researchers selected 14 (22) or 12 (23) TFs that are related to liver development and function. FoxA proteins are known as 'pioneer factors' that facilitate transcription of silent genes (44, 45) . Pioneer factors act as essential regulators of cell fate during normal development. They direct differentiation of various cell types via interaction with chromatin and subsequent cooperation with lineage-specific TFs (4). Since FoxA is expressed broadly throughout the endoderm, the other TFs are thought to specify hepatocyte fate commitment. During liver differentiation, FoxA recruits activators such as Hnf4a to activate albumin (Alb) transcription, which initiates the liver gene expression program (4, 46) . Thus, the use of FoxA might enable efficient conversion to iHep cells in the two methods (22, 23) .
Researchers were able to expand iHep cells in vitro while maintaining multiple hepatocyte-specific features. The cells mimicked hepatocyte expression patterns of genes involved in liver function. Indeed, iHep cells exhibited hepatic functions, including albumin secretion, urea production, triglyceride synthesis and drug metabolism. They were also able to engraft in the livers of mice lacking fumarylacetoacetate hydrolase (Fah -/-) (22, 23) , a common animal model of liver failure (47) . In contrast, another group reported that iHep cells have coincident hepatic and intestinal gene expression signatures, as revealed by CellNet (48) . CellNet reconstructs gene regulatory networks using publicly available gene expression data for a range of cell types and tissues, which allows the platform to assess the similarity of engineered cells to their targets (49) . Consistent with this analysis, iHep cells engrafted in large intestine and differentiated into functional intestinal cells (48) . In addition, the immature gene expression profile and long-term self-renewal seen in iHep cells more closely resemble a developmental intermediate than a fully differentiated hepatocyte (4). Thus, restricted specification of iHep cells to a mature hepatocyte fate may lead to more efficient engraftment in the liver when transplanted.
Two groups developed related methods to generate human iHep (hiHep) cells from fibroblasts (24, 25) . The expandable hiHep cells were converted via forced expression of HNF1a, HNF4a, FOXA3 and SV40 large T antigen (SV40-LT) (25) , or expression of HNF1a, HNF4a, HNF6, ATF5, PROX1, CEBPA, and c-MYC, and p53 shRNA (24) (Fig. 1A) . These conversion methods would be suitable for large-scale production of human hepatocytes (50) . The induced cells have metabolic activity, including CYP3A4 activity, comparable to that of primary hepatocytes. Of note, they also have the capacity to repopulate the injured livers of immunodeficient mice, suggesting that they are a promising source for cell therapy. However, for transplantation into human livers, generation of cells with integration-free methods using plasmids and/or small molecules would be preferable. Plasmid-based iHep cell conversion from mouse fibroblasts has been demonstrated ( Fig. 1C ) (51) . Mouse embryonic fibroblasts (MEFs) were transfected with oriP/Epstein-Barr Nuclear Antigen-1 (EBNA-1)-based episomal plasmids containing Gata4, Hnf1a and Foxa3, and generation of integration-free iHep cells was confirmed (Fig. 1C) (51) .
Small Molecules Support Conversion of Hepatocyte-Like Cells
Recent works have proved that somatic cells can be reprogrammed using small molecules, rather than forced expression of TFs. The Deng group demonstrated that fibroblasts can be converted to pluripotent stem cells using a cocktail of 10 small molecules, without genetic manipulation of TF expression (39, 40) . The resulting cells are authentic pluripotent stem cells, as demonstrated by germline transmission in the generated chimeras. Among the 10 small molecules, half are specific inhibitors for epigenetic regulators such as histone deacetylase, histone methyltransferase and DNA methyltransferase. These inhibitors might erase epigenetic memory, leading to full reprogramming. The same group also demonstrated direct conversion of mouse fibroblasts to functional neurons using four small molecules (52) . During the reprogramming, the fibroblast-specific program was suppressed by I-BET151, an inhibitor of the bromodomain and extra terminal domain protein (BET) family, by modulating the assembly of histone acetylation-dependent chromatin complexes, while neuronal genes were enhanced by the neurogenesis inducer ISX9. Cardiomyocytes were also generated from human fibroblasts by treatment with nine small molecules, without genetic manipulation of TF expression (38) . The small molecules include BIX01294, which inhibits histone lysine methyltransferase, and AS8351, which inhibits histone demethylase. These studies suggest that small molecules that modify epigenetic status are required for direct conversion in the absence of forced expression of TFs.
Substitution of small molecules for forced TF expression was also addressed in the context of iHep cell generation (53) . Mouse fibroblasts were converted to iHep cells by forced expression of a single TF, Hnf1a, in combination with treatment with two small molecules that inhibit TGF-b and GSK3b signaling (Fig. 1B) . The TGF-b inhibitor, A-83-01, induced rapid inactivation of the fibroblast program and accelerated the activation of the mesenchymal-to-epithelial transition (MET) (53) . The identification of additional small molecules that promote hepatic specification in combination with the TGF-b and GSK3b inhibitors will enable full replacement of TF manipulation.
Conversion of Hepatocytes to Culturable Liver Progenitor Cells by Small Molecules
Huge numbers of cells with repopulation capacity are required for cell transplantation therapy in humans. Katsuda et al. addressed in vitro expansion of mature rat and mouse hepatocytes (43) . They performed a mini chemical screening assay based on four small molecules, termed YPAC (Rho-associated coiled-coil (ROCK) inhibitor Y-27632, MAPK/ERK kinase (MEK) inhibitor PD0325901, A-83-01 and GSK3
inhibitor CHIR99021). The potential of YPAC for stem cell culture was shown when establishing rat ES cells (54) and multipotent mammary tumor cells (55) . Of the 16 possible combinations, a cocktail of Y-27632, A-83-01 and CHIR99021 (termed YAC) endowed mature hepatocytes with the highest proliferative capacity. These cells acquired the bipotent properties of liver progenitor cells, which differentiate into both hepatocytes and biliary epithelial cells. Of note, CLiPs have a repopulation capacity of 7590% when transplanted into chronically injured liver, which is comparable to transplantation of fresh hepatocytes. The repopulated cells differentiated into functional mature hepatocytes, which cured chronic liver disease in mice (Fig. 2) . Though the conversion mechanism of CLiP cells has not been elucidated, YAC might facilitate reprogramming of hepatocytes in a manner similar to the conversion of fibroblasts into iHep cells, as A-83-01 and CHIR99021 were used in both systems (43, 53) . Treatment with YAC, composed of only three small molecules, might induce partial reprogramming to the liver progenitor state, unlike the full reprogramming Cell fate conversion into the hepatic lineage achieved with the cocktail of 10 small molecules (40) . If the method of partial reprogramming can be adapted to somatic cells of other tissues, various progenitor cells can be generated for the broad application of cell-based therapy. In fact, non-tissue-specific, multipotent endodermal progenitor cells (EndoPC) were generated from human gastric epithelial cells using four small molecules, along with support from tissuespecific mesenchymal feeders (56) . The small molecules include TGF-b inhibitor SB431542, in addition to epigenetic modulators such as BIX01294 and RG108, and Ca 2+ -channel activator Bay K 8644. The multipotent EndoPCs have the potential to differentiate into pancreatic endocrine cells, intestinal epithelia and hepatocytes (Fig. 2) . As the differentiated hepatocyte-like cells could engraft in the livers of Fah -/-mice, in the future, multipotent EndoPCs could be developed for cell therapy for human liver diseases.
Conclusion
The methods for generating culturable sources of cells for liver transplantation have progressed dramatically since the recent development of reprogramming strategies via genetic manipulation of TFs and treatment with small molecules. The development of integration-free human cells such as iHep and CLiP cells will be required for clinical use. In addition, ES cells, iPS cells, mesenchymal stem cells, liver organoids and EndoPCs may also be useful for the generation of transplantable hepatocytelike cells by according to appropriate differentiation protocols using small molecules and growth factors (Fig. 2) . New methods for generating hepatocyte-like cells will likely be developed in the future; in combination with the current methods, they may produce induced hepatocyte-like cells for the first successful cell-based transplantation therapy for human liver diseases. 
